Although LRRK2 is a sought-after target for PD, the exact signaling pathways that link LRRK2 with PD pathology are unknown. LRRK2 is a large (286 KD), multi-domain protein that has two enzymatic domains and several other moieties involved in protein-protein interactions. However, LRRK2 kinase inhibitors are the most frequently used, if not the only, pharmacological tools for the study of LRRK2 biology, leaving the GTPase domain and protein-protein interaction domains of LRRK2 underexamined. The LRRK2 degrader that we have developed and characterized in this study offers a new chemical tool for deciphering the biology of LRRK2.